These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 26233732)

  • 1. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
    Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
    Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
    Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
    Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
    Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
    PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
    Hosoya T; Kimura K; Itoh S; Inaba M; Uchida S; Tomino Y; Makino H; Matsuo S; Yamamoto T; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H
    Trials; 2014 Jan; 15():26. PubMed ID: 24433285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China.
    Yang H; Li R; Li Q; Yan T; Li Y; Huang Q; Uchida S; Chang W
    Int Urol Nephrol; 2023 May; 55(5):1343-1352. PubMed ID: 36534221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
    Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
    Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
    Lee JW; Lee KH
    Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.
    Kohagura K; Satoh A; Kochi M; Nakamura T; Zamami R; Tana T; Kinjyo K; Funakoshi R; Yamazato M; Ishida A; Sakima A; Iseki K; Arima H; Ohya Y
    J Hypertens; 2023 Sep; 41(9):1420-1428. PubMed ID: 37334544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is It Time to Start Treating Asymptomatic Hyperuricemia?
    Levy G; Cheetham TC
    Am J Kidney Dis; 2015 Dec; 66(6):933-5. PubMed ID: 26593311
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study.
    Yamaguchi A; Harada M; Yamada Y; Hashimoto K; Kamijo Y
    BMC Nephrol; 2017 May; 18(1):162. PubMed ID: 28521802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
    Yang AY
    Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
    Stack AG; Dronamraju N; Parkinson J; Johansson S; Johnsson E; Erlandsson F; Terkeltaub R
    Am J Kidney Dis; 2021 Apr; 77(4):481-489. PubMed ID: 33130235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
    Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
    Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease.
    Nagaraju SP; Shenoy SV; Rao I; Prabhu RA; Rangaswamy D; Bhojaraja MV; Guddattu V
    Saudi J Kidney Dis Transpl; 2023 Jul; 34(4):279-287. PubMed ID: 38345582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Febuxostat-Associated Myopathy in Patients with CKD.
    Liu CT; Chen CY; Hsu CY; Huang PH; Lin FY; Chen JW; Lin SJ
    Clin J Am Soc Nephrol; 2017 May; 12(5):744-750. PubMed ID: 28302902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.
    Goicoechea M; Garcia de Vinuesa S; Verdalles U; Verde E; Macias N; Santos A; Pérez de Jose A; Cedeño S; Linares T; Luño J
    Am J Kidney Dis; 2015 Apr; 65(4):543-9. PubMed ID: 25595565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
    Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
    J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia.
    Pingali U; Nutalapati C; Koilagundla N; Taduri G
    BMC Complement Med Ther; 2020 Sep; 20(1):281. PubMed ID: 32933504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort
.
    Aoun M; Salloum R; Dfouni A; Sleilaty G; Chelala D
    Clin Nephrol; 2020 Aug; 94(2):61-69. PubMed ID: 32589132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.